Deloitte, a global leader in consulting and advisory services, has just expanded its innovative Quartz AI™ suite with the addition of Atlas AI™, specifically designed to revolutionize the drug discovery process. Announced on January 8, 2024, Atlas AI™ is the first offering in the life sciences and health care sector under the Quartz umbrella, designed to significantly accelerate research and the introduction of new drugs to the market.
Atlas AI™ is a first-of-its-kind Generative AI solution that synergizes NVIDIA BioNeMo cloud APIs with Deloitte’s extensive industry experience and a team of skilled AI professionals. This pioneering approach aims to reimagine the drug discovery process by integrating Generative AI models, knowledge representation, reasoning, and custom Large Language Models (LLMs) for both protein and chemoinformatics.
Dan Ferrante, AI leader for innovation and R&D at Deloitte Consulting LLP, emphasizes the transformative potential of Atlas AI™. “Atlas AI represents a leap in how Generative AI and Large Language Models can facilitate deeper data insights and more efficient human-machine collaboration, providing real-world value. This is about saving crucial research time and bringing together data, language models, and AI-powered scientific pipelines in a no-code interface,” he said.
This advanced platform combines NVIDIA’s BioNeMo™ cloud APIs for intelligent chemical and protein design, structure prediction, and mapping with Deloitte’s proprietary Generative AI models. This collaboration allows for the identification of the most effective applications for new drugs. Additionally, Deloitte’s recent acquisition of SFL Scientific has bolstered its molecular modeling and drug discovery team, enhancing the capabilities of Atlas AI™.
Leveraging the NVIDIA Omniverse platform, Atlas AI™ offers an immersive, collaborative 3D environment for scientists to simulate drug discovery experiments. This integration signifies a significant stride in digital biology, transforming drug discovery with the latest AI technologies.
Kimberly Powell, Vice President of Healthcare at NVIDIA, highlighted the broad implications of this collaboration. “Enterprises in various sectors, especially healthcare and life sciences, are looking for innovative ways to leverage Generative AI. Atlas AI™, built using NVIDIA BioNeMo, is set to equip clients with essential tools to innovate more quickly and competitively,” she stated.
The introduction of Atlas AI™ is a part of Deloitte’s strategic expansion with NVIDIA, aiming to unlock Generative AI’s value across enterprise software platforms. This includes the establishment of an Ambassador AI program to support clients in advancing their AI journeys using NVIDIA AI foundation models and the NVIDIA NeMo LLM framework.
As Deloitte continues to expand its Generative AI practice, it remains committed to the safe and responsible use of AI. Guided by its Trustworthy AI™ framework, Deloitte ensures necessary safeguards are in place, mitigating risks during product development and operation, and reinforcing its leadership in the AI marketplace.
The launch of Atlas AI™ is more than just a technological advancement; it’s a step towards a future where drug discovery is faster, more efficient, and more attuned to patient needs, heralding a new era in healthcare innovation.